News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
266,150 Results
Type
Article (14397)
Company Profile (258)
Press Release (251495)
Section
Business (81176)
Career Advice (159)
Deals (13626)
Drug Delivery (29)
Drug Development (51187)
Employer Resources (31)
FDA (6137)
Job Trends (5345)
News (148205)
Policy (10957)
Tag
Academia (936)
Africa (164)
Alabama (26)
Allergies (31)
Alliances (21895)
Alzheimer's disease (694)
Antibody-drug conjugate (ADC) (30)
Approvals (6104)
Arizona (41)
Artificial intelligence (26)
Asia (17027)
Australia (2864)
Bankruptcy (124)
Best Places to Work (4534)
Biotechnology (214)
C2C Services and Suppliers (12033)
California (1110)
Canada (462)
Cancer (204)
Career advice (140)
CAR-T (32)
Cell therapy (82)
China (73)
Clinical research (39797)
Collaboration (70)
Colorado (33)
Compensation (28)
Connecticut (35)
COVID-19 (1032)
Cystic fibrosis (58)
Data (118)
Diabetes (31)
Diagnostics (1188)
Earnings (29332)
Employer resources (29)
Europe (36547)
Events (46644)
Executive appointments (74)
FDA (6230)
Florida (115)
Funding (76)
Gene therapy (71)
GLP-1 (258)
Government (1152)
Healthcare (6924)
Hotbed/Location (191432)
Illinois (69)
Indiana (44)
Infectious disease (1040)
Inflammatory bowel disease (77)
IPO (7313)
Job creations (886)
Job search strategy (134)
Kansas (54)
Layoffs (182)
Legal (1757)
Lung cancer (43)
Maryland (173)
Massachusetts (889)
Medical device (2983)
Medtech (2983)
Mergers & acquisitions (6280)
Metabolic disorders (114)
Michigan (35)
Minnesota (68)
Neuroscience (785)
New Jersey (303)
New York (348)
NextGen Class of 2024 (2115)
Non-profit (1005)
North Carolina (339)
Northern California (497)
Obesity (68)
Ohio (60)
Opinion (90)
Parkinson's disease (26)
Patents (35)
Peanut (28)
Pennsylvania (253)
People (25019)
Pharmaceutical (42)
Phase I (13777)
Phase II (18354)
Phase III (11971)
Pipeline (65)
Postmarket research (932)
Preclinical (5790)
Press Release (30)
Rare diseases (93)
Real estate (1445)
Regulatory (8468)
Research institute (950)
South America (230)
Southern California (457)
Startups (1994)
Texas (95)
United States (4318)
Vaccines (122)
Washington State (143)
Weight loss (53)
Date
Last 7 days (360)
Last 30 days (1169)
Last 365 days (21962)
2024 (14791)
2023 (22947)
2022 (27554)
2021 (28655)
2020 (24402)
2019 (17035)
2018 (12512)
2017 (14289)
2016 (12355)
2015 (14972)
2014 (10857)
2013 (7869)
2012 (7935)
2011 (8042)
2010 (7808)
266,150 Results for "relief therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting
RELIEF THERAPEUTICS Holding SA announces the results of its annual general meeting (AGM) of shareholders, which took place in Geneva today.
June 27, 2024
·
3 min read
Business
Relief Therapeutics Announces Executive Changes - June 4, 2024
RELIEF THERAPEUTICS Holding SA today announced that interim Chief Executive Officer Michelle Lock has completed her transitional mandate with the Company.
June 3, 2024
·
2 min read
Relief Therapeutics Announces Notice of Annual General Meeting of Shareholders
RELIEF THERAPEUTICS Holding SA announced the Annual General Meeting of shareholders will take place on Thursday, June 27, 2024, at 11:00 a.m. CEST at Campus Biotech, chemin des Mines 9, 1202 Geneva, Switzerland.
May 30, 2024
·
3 min read
Business
Relief Therapeutics has Published its Annual Report
RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, published its Annual Report 2023 and provided a corporate update.
April 30, 2024
·
2 min read
RELIEF THERAPEUTICS Holding SA Announces Results of Extraordinary General Meeting
RELIEF THERAPEUTICS Holding SA announces the results of the extraordinary general meeting of shareholders, which took place in Geneva , Friday, April 26, 2024.
April 26, 2024
·
4 min read
Business
Logix Biosciences Enters into Agreement with Mayo Clinic to Advance Development of Therapeutics for Allergy Relief, Mutating Infectious Diseases and Antimicrobial Resistance
Logix Biosciences, a biopharmaceutical company focused on the discovery and development of a pipeline of precision therapeutics and companion diagnostics for allergy relief, protection against infectious diseases, and antimicrobial resistance (AMR), today announced it has entered into a know-how agreement with Mayo Clinic.
June 12, 2024
·
2 min read
Press Releases
Relief Therapeutics Announces PKU GOLIKE Study Results Presentation at SSIEM 2024
September 2, 2024
·
3 min read
Business
Relief Therapeutics Announces New Executive Leadership Team Strengthening Capabilities to Guide the Company through Pipeline Development Initiatives
RELIEF THERAPEUTICS Holding SA announced the formation of its new executive committee strengthening its capabilities with the appointment of several new members, including a chief financial officer, chief human resources officer and head of legal and compliance.
May 8, 2024
·
5 min read
Press Releases
Relief Therapeutics Reports Half-Year 2024 Financial Results and Provides Corporate Update
August 30, 2024
·
2 min read
Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE
RELIEF THERAPEUTICS Holding SA announced it has granted an exclusive license to Eton Pharmaceuticals, Inc. for the commercialization of GOLIKE ® family of products in the United States.
March 22, 2024
·
6 min read
1 of 26,615
Next
